{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046055","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.958266+00:00","generated_at":"2026-05-24T03:53:43.208938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations","bullets":["Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.","Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.","Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.","Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.","FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046055","json":"https://secwatch.observer/filing/0000950170-25-046055.json","markdown":"https://secwatch.observer/filing/0000950170-25-046055.md","text":"https://secwatch.observer/filing/0000950170-25-046055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/0000950170-25-046055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/tpst-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:53:43.208938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}